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Bioavalaibility and pharmacokinetic comparison of two formulations
of metformin 850 mg tablets in healthy Colombian volunteers
GLORIA HOLGUÍN, ESP1, FANNY CUESTA, IQ2, ROSENDO ARCHBOLD, MSC3,
MARGARITA RESTREPO, MSC4, SERGIO PARRA, MSC5, LINA PEÑA, ESP6,
BLANCA MONTOYA, BACT7, JUAN CARLOS RÍOS, MSC8, VICTORIA EUGENIA TORO, QF9,
ADRIANA RUIZ, PhD10
SUMMARY
Purpose: The aim of this study was to compare the bioavailability of two formulations of metformin 850 mg
tablets: Glucophage® from Merck Santè laboratories (reference product) and Metformin from Winthrop
Pharmaceuticals de Colombia SA (test product) in healthy Colombian volunteers.
Methods: A random, double blind, two-period, two-week wash out period, crossover study was performed in
24 healthy male and female volunteers for a single 850-mg dose of metformin tablets administrated with 240 ml
of water after 12 hours of fasting. Once the drug was administrated, blood samples were collected before and within
24 hour, and plasma metformin concentration was determined by using a validated HPLC method. Pharmacokinetic
parameters such as Cmax, AUC0-96h, AUC0-OO, and Tmax were determined. The formulations were considered
bioequivalent if the logarithmic mean ratios of ln-transformed Cmax and AUC0-OO values were within the
equivalence range of 80%-125%.
Results: ANOVA analysis of the ln-transformed Cmax and AUC0-OO indicated that none of the effects examined
(formulation, period, within and between-subjet variances and carry over) was statistically significant. The mean
(±SD) of Cmax 1217.38 (± 251.72) ng/ml vs. 1305.25 (± 301.06) ng/ml, AUC0-96h 1363.49 (± 315.51) ng.h/ml vs.
1584.82 (± 368.75) ng.h/ml, AUC0-OO, 7155.75 (± 1440.74) ng.h/ml vs. 7777.08 (± 1896.49) ng.h/ml, and Tmax 2.57
(± 0.93) h vs. 2.22 (± 0.94) h were obtained with test and reference formulations, respectively. These
pharmacokinetic parameters presented differences with the results from other published papers. The 90%
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confidence interval of the logarithmic ratio of AUC0-OO
and Cmax was within the range of 80-125%.
Conclusions: In this study in healthy Colombian
volunteers, a single 850-mg dose of metformin tablet
test formulation met the criteria for bioequivalence to
the reference formulation based on pharmacokinetic
parameters AUC0-OO and Cmax.
Keywords: Metformin; Bioequivalence; Bioavailability;
Pharmacokinetics; Interchange of drugs;
Area under curve.
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Comparación de la biodisponibilidad y la farmaco-
cinética entre dos formulaciones de tabletas de metfor-
mina de 850 mg en voluntarios colombianos sanos
RESUMEN
Objetivo: El objetivo de este estudio es comparar la
bioequivalencia de dos formulaciones de tabletas de
metformina de 850 mg: Glucophage® del Laboratorio Merck
Santè (producto de referencia) y metformina de Laboratorios
Winthrop Pharmaceuticals de Colombia SA (producto de
prueba), en voluntarios colombianos sanos.
Métodos: Se realizó un estudio aleatorizado, doble ciego,
cruzado, en dos períodos y con un tiempo de lavado de dos
semanas, en 24 voluntarios sanos, hombres y mujeres, que
recibieron una dosis única de metformina de 850 mg, con 240
ml de agua, después de 12 horas de ayuno. Luego de la
administración del medicamento, se recolectaron muestras
de sangre durante 24 horas y las concentraciones plasmáticas
de metformina se determinaron con un método de HPLC
validado. Se calcularon los parámetros farmacocinéticos:
Cmax, AUC0-96h, AUC0-OO, y Tmax. Las formulaciones se consi-
deraron bioequivalentes si la relación de la media transfor-
mada a ln de Cmax y AUC0-OO estaba dentro del rango de
bioequivalencia de 80% a 125%.
Resultados: El Anova de los datos transformados a ln de
Cmax y AUC0-OO indicaron que ninguno de los efectos analiza-
dos (formulación, período, variación intra e intersujetos y
arrastre) fueron estadísticamente significativos. La media
(±SD) de los parámetros obtenidos para los productos de
prueba y de referencia, respectivamente, fueron: Cmax 1217.38
(± 251.72) ng/ml vs. 1305.25 (± 301.06) ng/ml, AUC0-96h
1363.49 (± 315.51) ng.h/ml vs. 1584.82 (± 368.75) ng.h/ml,
AUC0-OO, 7155.75 (± 1440.74) ng.h/ml vs. 7777.08 (± 1896.49)
ng.h/ml, and Tmax 2.57 (± 0.93) h vs. 2.22 (± 0.94) h. El
intervalo de confianza de la relación logarítmica del AUC0OO
y Cmax se encontró dentro del rango de 80% a 125%.
Conclusiones: En este estudio en voluntarios sanos co-
lombianos, la comparación de una formulación de prueba de
tabletas de metformina de 850 mg, con una formulación de
referencia, cumplió los criterios de bioequivalencia teniendo
como base los parámetros farmacocinéticos AUC0-OO and
Cmax.
Palabras clave: Metformina; Bioequivalencia;
Biodisponibilidad; Farmacocinética;
Intercambiabilidad de medicamentos; Área bajo la curva.
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Metformin is a biguanide drug that became commer-
cially available in 1957. It is for oral administration and
has a specific anti-hyperglycemic effect on patients
with type 2 diabetes mellitus (DM). Therapeutic doses
of metformin do not produce hypoglycemia, and it is a
therapeutic advantage when compared with sulfony-
lureas1.
Doses of 0.5-1.5 g have a bioavailability of 50%-
60%2. Absorption is slow and incomplete in the upper
gastrointestinal tract, because of the high polarity and
low liposolubility of the molecule. At intestinal pH
between 7 and 8, metformin is mainly ionized (pka=2.8
and 11.5), which slows its absorption rate3.
Metformin is rapidly distributed after absorption,
and it is accumulated in the esophagus, stomach, duo-
denum, salivary glands, and kidneys4. It has neither
binding to plasma proteins nor metabolism, and it
undergoes renal excretion.
Nowadays, metformin is a first-choice drug for type
2 DM treatment because of its broad therapeutic
advantages. Therefore, Colombian pharmaceutical
industries have been motivated to produce a generic
form of this drug.
Because of the low bioavailability and high inter-
individual variability in the absorption of the different
pharmaceutical forms of metformin, it is necessary to
perform comparative bioavailability studies. Thus,
regulatory authorities and medical prescribers would
have the scientific support to expect a therapeutic
equivalence if bioequivalence among the compared
pharmaceutical forms is demonstrated.
The aim of this study was to evaluate, in healthy
Colombian volunteers, the bioequivalence of the generic
metformin, from Laboratorios Lakor Farmacéutica SA
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now Winthrop Pharmaceuticals de Colombia SA
manufactured by Sanofi~Synthelabo, Cali, Colombia,
with the reference product Glucophage® from Merck
Santè laboratories.
MATERIALS AND METHODS
Drug products. Test product (T): metformin, 850-
mg tablets, owned by Winthrop Pharmaceuticals de
Colombia SA manufactured by Sanofi~Synthelabo,
Cali, Colombia, lot: P1320804, and containing 850 mg
of the active ingredient per tablet, corresponding to
100% of the labeled quantity of metformin.
Reference product (R): Glucophage®, 850 mg
tablets, owned by Merck, manufactured by Merck
Santè, Lyon, France, lot: 104031, and containing 872.95
mg of the active ingredient per tablet, corresponding to
the 102.7% of the labeled quantity of metformin.
The pharmaceutical products used in this study were
previously evaluated to determine the drug content of
each product, according to the British Pharmacopoeia
Quality Specifications. They were declared pharma-
ceutical equivalents because the test product did not
differ from the reference product by more than 5%.
Study subjects. The study was conducted according
to the Helsinki Declaration and Resolution 8430 of
1993 by the Ministry of Social Protection. It was also
approved by the Ethics Committee of the School of
Medicine, at Universidad de Antioquia. 24 subjects
were recruited for this study, (10 male, 14 female; ages
21.2±2.1 years; weight 60.5±7.7 kg; height 1.67±0.08
m). Subjects were assessed healthy volunteers, after
having been medically examined and clinically tested:
complete blood count, urinalysis, blood biochemistry
were normal, and HIV, hepatitis B, and pregnancy
screenings (for women) were negative. All subjects
were briefed on the bioequivalence study details and
they all agreed and signed a written informed consent.
All volunteers were free to leave the study at any time.
The number of subjects was determined by the
coefficient of variation from published data5 and by
applying the method proposed by Zapater6 and Julious7
to obtain 80% power.
Clinical trial design. In order to evaluate the
bioequivalence of the two metformin formulations, we
performed a random, double blind, two-period crossover
study. On the first dosing day, each subject took a
metformin tablet of either test or reference formulations
(850 mg of metformin) with 240 ml of water. After a 2-
week wash out period, each subject took a tablet of the
other product.
The volunteers for this study were admitted to the
Corporación de Estudios en Salud clinic (CES) in
Medellín (Colombia), and they were under direct
medical supervision during 24 hours. The first day at
6:00 am, their urine samples were tested for alcohol and
drug abuse. Subjects received formulations after 12
hours of fasting.
Standard breakfast, lunch, refection, and dinner
were given at 2, 5, 8, and 11 hours after dosing. All
meals were the same for both periods. Food with
xanthines (such as chocolate), and carbonated drinks
were not allowed.
Ten milliliter blood samples were taken through an
indwelling cannula in heparinized tubes (Becton
Dickinson, NY) before (0.0 h) and at 0.50, 1, 1.50, 2,
2.50, 3, 3.50, 4, 5, 6, 8, 10, 12, 14, and 24 hours after
drug administration. Samples were centrifuged at 2000
rpm for 15 minutes and plasma was separated and
stored at -20°C for analysis.
Analytical procedure and method validation.
Metformin extraction from plasma was accomplished
by the liquid-liquid extraction method proposed by
Yuen et al.8 One half ml of plasma was vortex during 30
seconds in a screw-capped glass tube after adding 2 ml
of acetonitrile to precipitate plasma proteins. After
centrifugation (2500 rpm) for 5 minutes at 5ºC, 2 ml of
supernatant was transferred to another clean glass tube.
The drug was extracted with 2 ml of the extraction
solvent (n-hexan) and vortex for thirty seconds followed
by centrifugation (2800 rpm) for 5 minutes. The organic
phase was then transferred by aspiration to a clean glass
tube. The extraction procedure was repeated with the
remaining samples. A gentle air flow and a water bath
were used to dry the organic phase. The residue was
reconstituted in 400 µl of a mixture of KH2PO4 buffer
10 mM (pH 7.5) and acetonitrile (72:28, v/v), and
filtered by using a vacuum pump. One hundred micro-
litres of the sample were injected directly into a
chromatographic system.
The HPLC system is comprised of an Agilent,
model HP1100 (California, USA), pump, an Agilent
diode array detector, and an auto-injector. The software
package ChemStation (2000 Version) was used to
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control the chromatographic system. The Analytical
column was a LiChrospher C18 RP-Select B (Agilent,
250 mm, 4 mm ID, 5 µm particle size). The mobile
phase consisted of dihydrogen phosphate buffer 0.01M
(pH 7.5) and acetonitrile (40:60 v/v). The flow rate was
1.5 ml/min.
The method was validated following criteria
established by FDA Guidelines9. Calibration was linear
in the concentration range of 62.5-2000.0 ng/ml, with
an intra-day correlation coefficient of 0.9995 and inter-
day of 0.9976. The intra-day and inter-day calibration
curve showed consistent linearity, as seen by a slope
coefficient of variation (CV) of 7.6% and 9.6%,
respectively.
Other validation parameters were also fulfilled by
this method. Intra-day precision was determined by
replicate analysis (six times) of standard samples in
plasma containing 125, 500, and 2000 ng/ml. Intra-day
precision in this study, expressed as means of percent of
CV, was 7.3%.
Inter-day precision was determined at six
concentrations (62.5, 125, 250, 500, 1000, and 2000 ng/
ml) in plasma, in six replicate runs (6 days). Inter-day
precision in this study expressed, as the mean of CV
was 12.3%. The limit of quantification based on CV
smaller than 20% was 62.5 ng/ml; estimated on values
obtained in intra-day and inter-day assays.
Two concentrations of metformin (250 and 1000 ng/
ml-quality control (QC) samples in three replicates
were used for stability studies, including freeze and
thaw, short-term temperature and long-term stability;
they fulfilled validation parameters. Standard curves
were performed daily, over a 12-week period, with each
volunteer’s plasma samples and showed consistent
linearity (intercept, slope, and correlation coefficient).
Pharmacokinetic analysis. Pharmacokinetic data
were calculated by non-compartmental method. The
maximum plasma concentration (Cmax) and the time to
reach it (Tmax) were determined by inspecting each
individual plasma level-time curves. The elimination
rate constant (ke) was obtained by ln-linear regression
of the terminal decay phase. The area under the plasma
level-time curve (AUC0-96h) was obtained by the
trapezoidal rule, and the AUC96h-OO time was determined
by dividing the last plasma concentration by ke, and
adding this result to the AUC0-96h. The partial AUC (as
an early exposure measure) was obtained by truncating
the partial area at the population median of Tmax values
for the reference formulation.
Statistical analysis. In order to assess the effects of
treatment, period, sequence of administration, and
subjects, ln-transformed data for AUC0-OO and Cmax, and
non-transformed Tmax were evaluated by means of
analysis of variance (ANOVA) for the cross design
(Statistica 6.0, Statsoft Inc, 2001).
The method suggested by Schuirmann and accepted
by the FDA10 (known as the two one-sided tests) was
used to evaluate whether these two formulations of
metformin were bioequivalent. Bioequivalence was
accepted if 90% confidence intervals for test/reference
ratios of AUCs and Cmax fell in the range of 0.80-1.25.
A p value of less than 0.05 was considered statistically
significant11.
RESULTS
At the first period, all 24 subjects concluded the
study without any adverse effects. However, in the
second period, one subject presented diarrhea with the
test product, another reported epigastric pain with the
reference product. At the beginning of this period, a
subject was excluded because she was taking antibiotics
to treat a urinary infection. Pharmacokinetic parameters
were calculated for all 23 volunteers who ended the
second period.
Concentrations over the quantification limit (62.5
ng/ml) were observed within 5 to 14 hours. Although
blood samples were taken until 24 hours after drug
administration, plasma levels were not detected at this
time. The mean concentration profiles for the 2 formu-
lations were quite similar, as observed in Figure 1.
To obtain paired data for 22 subjects, one of 23 was
excluded randomly. All parameters had normality for
intra-subject and inter-subject residues. However, two
volunteers presented extreme outcomes: one had lower
AUC0-OO and early exposure area (AUC0-Tmax) values for
the test as compared with the reference formulation;
Tmax was also very different in this volunteer (test 5
hours, and reference 1.5 hours). The other one had
higher AUC0-Tmax values for the test as compared with
the reference formulation. The pharmacokinetic
parameters for both formulations are shown in Table 1.
The mean values and 90% CI for the pharmacokinetic
parameters compared are summarized in Table 2.
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Figure 1. Comparison of plasma metformin concentrations (mean ± SEM) after a single
oral administration of test or reference products (tablets of 850 mg) in 22 healthy volunteers
Table 1
Pharmacokinetic parameters after administration of 850 mg of test and reference
formulations of metformin in healthy Colombian volunteers (n=22)
Parameter     Test mean (SD) Reference mean (SD)
Cmax, ng/ml 1217.38 (251.72) 1305.25 (301.06)
Tmax, h 2.57 (0.93) 2.22 (0.94)
AUC0-96, ng.h/ml 6786.81 (1410.86) 7357.10 (1808.78)
AUC0-Tmax, ng.h/ml 1363.49 (315.51) 1584.82 (368.75)
AUC0-OO, ng.h/ml 7155.75 (1440.74) 7777.08 (1896.49)
t1/2, h 2.62 (0.40) 2.77 (0.33)
ke, h




















ANOVA for AUC0-OO and Cmax, after logarithmic
transformation of the data, revealed that none of the
effects examined (formulation, period, within and
between-subject variances and carry over) was
statistically significant. The 90% CI was within the
bioequivalence acceptable range from 80% to 125%,
suggesting that both formulations are similar.
DISCUSSION
Although we planned a study with 24 volunteers, we
had to exclude two of them; nevertheless, the power test
Table 2
Confidence intervals (90%) for ln-transformed
parameters (Cmax and AUC0-OO) of two metformin
tablet formulations after a single-dose
administration to healthy Colombian volunteers
(n=22)
Parameter             Test/Reference ratio   90% CI
AUC0-OO, ng.h /ml 0.991 84.9-100.8
Cmax (ng/ml) 0.991 86.0-102.5
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calculated by using the variability data obtained in the
ANOVA analysis and the equations proposed by Julious7
revealed that a sample size of 22 volunteers was sufficient
to reject bio-inequivalence (power 88.3%).
The available pharmacokinetic data on metformin
have shown that oral bioavailability, ranges from
approximately 32% to 61%. The drug disposition
exhibits multi-compartmental characteristics. Met-
formin is rapidly eliminated by the kidney by combined
glomerular filtration and tubular secretion. Its meta-
bolism and protein-binding in plasma are negligible.
Studies with small numbers of patients suggest that
bioavailability decreases with increasing dose12. There
are only scarce data on the relationship between plasma
metformin concentrations and metabolic effects13.
Pharmacokinetic parameters such as ke, t1/2, and
Cmax, present large differences when several papers are
compared5,14,15 including the results obtained in this
study and in another research we conducted16. This
variability could be explained by the metformin accu-
mulation in the intestinal wall17, the subject variation
attributed to the drug transporter polymorphisms18, and
physiological factors, such as gastric emptying and
small-intestine transit. Changes in the gastric emptying
and intestinal transit of a metformin dosage form may
alter absorption processes and, therefore, bio-
availability19.
The reference product reached slightly higher
plasmatic levels than the test product and the amount
absorbed seemed to be slightly greater (Figure 1).
Although there was no significant difference for Cmax
and AUC0-OO, the Tmax parameter showed a higher inter-
subject variability, with one subject being the most
extreme case, who showed a Tmax for the test product of
5 hours, while for the reference product it was 1.5
hours. For this reason, the partial AUC0-Tmax was
measured.
The variability in Tmax had implications on the
AUC0-Tmax, the 90% CI calculated for this parameter
was 78.9-93.5 %, out the range of 80-125%. We might
explain this result by the drug class, because in the
biopharmaceutical classification it belongs to a
substance with high solubility and low permeability
(Class III)20. In a solution, the permeability may be the
limiting factor for the absorption rate. Thus, the
absorption kinetics should be ruled more by physio-
logical conditions and the drug distribution than by
factors related with the formulation21.
The differences found in this study for the Tmax can
be demonstrated because it was performed with one
dose only; however, with the chronic administration
and the achievement of a stable concentration, no
clinical repercussions are expected for such difference.
Although several parameters are important at the
time of a product interchange, according to the FDA,
the extension of the absorption (AUC0-OO), and the Cmax
are the key parameters to declare the bioequivalence.
CONCLUSION
The generic product metformin, tablets of 850 mg,
is bioequivalent regarding AUC0-OO and Cmax when
compared with the reference product (Glucophage®).
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